skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Dronedarone for atrial fibrillation: a new therapeutic agent

Review

(5069) Views  (1701) Full article downloads

Authors: Pawan D Patel, Rohit Bhuriya, Dipal D Patel, et al

Published Date August 2009 Volume 2009:5 Pages 635 - 642
DOI: http://dx.doi.org/10.2147/VHRM.S6185

Pawan D Patel, Rohit Bhuriya, Dipal D Patel, Bhaskar L Arora, Param P Singh, Rohit R Arora

Department of Cardiology, Chicago Medical School, Chicago, IL, USA

Abstract: Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile. Dronedarone is a multichannel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation.

Keywords: dronedarone, amiodarone, atrial fibrillation








Readers of this article also read:

Safety and efficacy of rosiglitazone in the elderly diabetic patient
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Management of acute attacks of hereditary angioedema: potential role of icatibant
Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation
Effectiveness of coordination exercise in improving cognitive function in older adults: a prospective study
Erratum
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University